John‐Arne Røttingen

Wellcome Trust

@wellcometrust.bsky.social

Hello to everyone on Bluesky 👋

We’re a global charitable foundation. We believe science and research are essential to solving the world’s health challenges – and everyone should benefit from them.

Find out more about us ⤵️
wellcome.org/what-we-do?u...

What we do | Wellcome

Wellcome improves health for everyone by funding research, leading policy and advocacy campaigns, and building global partnerships.

wellcome.org

4 24 110

Reposted by John‐Arne Røttingen

by John‐Arne Røttingen

John-Arne Røttingen

@jarottingen.bsky.social

It was a pleasure to speak with Paul van Zyl of The Conduit on science and politics, climate and health. @wellcometrust.bsky.social will join the Climate and the Future of Health event this Monday, 23 June at The Conduit, London www.theconduit.com/view-from-th...

John-Arne Røttingen, CEO, The Wellcome Trust - The Conduit

“We have some underlying beliefs as an organization, believing in the power of science, believing that we need to interact with society, having equity as a north star. We have values related to being ...

www.theconduit.com

1 1

Reposted by John‐Arne Røttingen

by John‐Arne Røttingen

John-Arne Røttingen

@jarottingen.bsky.social

Superb to see so many recognised in science and public health in the King's birthday honours. Congratulations in particular to former @wellcometrust.bsky.social director of infectious disease Gordon Dougan and @lshtm.bsky.social director Liam Smeeth.

1 6

by John‐Arne Røttingen

Reposted by John‐Arne Røttingen

Aidan Warner

@aidanwarner.bsky.social

Spending review research commitments are "a reduction in ambition at a time when the UK desperately needs the economic growth that investing in science brings" Wellcome ceo @jarottingen.bsky.social says

John-Arne Røttingen, chief executive of Wellcome, the UK's largest non-governmental funder of research, said:

“The previous government planned to reach £22bn a year of R&D spending last year, then pushed it back. Today's review pushes that aim back further to 2030. This is a reduction in ambition at a time when the UK desperately needs the economic growth that investing in science brings.

“The squeeze on the health research budget in particular risks limiting our ability to find new treatments and innovation in the NHS. Britain has a strength in life sciences and medicine that it should be leaning into, to benefit patients and the economy.

“Meanwhile, a consequence of the disappointing decision to cut overseas aid is that the science it funds, tackling some of the world’s biggest health threats, will be halved by the end of the decade."

1 3

by John‐Arne Røttingen

References

Fields & subjects